Compare · GTH vs NTRA
GTH vs NTRA
Side-by-side comparison of Genetron Holdings Limited (GTH) and Natera Inc. (NTRA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GTH and NTRA operate in Medical Specialities (Health Care), so they compete in similar markets.
- NTRA carries a market cap of $41.68B.
- NTRA has hit the wire 33 times in the past 4 weeks while GTH has been quiet.
- NTRA has more recent analyst coverage (25 ratings vs 0 for GTH).
- Company
- Genetron Holdings Limited
- Natera Inc.
- Price
- -
- -
- Market cap
- -
- $41.68B
- 1M return
- -
- -28.06%
- 1Y return
- -
- +34.53%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2015
- News (4w)
- 0
- 33
- Recent ratings
- 0
- 25
Genetron Holdings Limited
Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early liver cancer screening services through laboratory developed tests services, such as HCCscreen, a proprietary assay for the early screening of hepatocellular carcinoma. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product based on semiconductor sequencing to detect lung cancer; Genetron 3D biochip reading instrument; IDH1 and TERT gene assays for glioma; Genetron S5 platform, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; and Genetron S2000 platform, a production-scale sequencer. In addition, the company develops ctDNA lung cancer assay for mutations in the epidermal growth factor receptor gene. Further, it offers development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies, hospitals, and research institutions worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People's Republic of China.
Natera Inc.
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Latest GTH
- SEC Form 15-12G filed by Genetron Holdings Limited
- SEC Form SC 13D/A filed by Genetron Holdings Limited (Amendment)
- SEC Form SC 13D/A filed by Genetron Holdings Limited (Amendment)
- SEC Form SC 13D/A filed by Genetron Holdings Limited (Amendment)
- SEC Form SC 13D/A filed by Genetron Holdings Limited (Amendment)
- SEC Form S-8 POS filed by Genetron Holdings Limited
- SEC Form 25-NSE filed by Genetron Holdings Limited
- SEC Form SC 13E3/A filed by Genetron Holdings Limited (Amendment)
- Genetron Health Announces Completion of Going Private Transaction
- SEC Form 6-K filed by Genetron Holdings Limited
Latest NTRA
- HLTH 2026 Names Natera Best-in-Class Winner in Cancer, Screening & Early Detection
- Amendment: SEC Form SCHEDULE 13G/A filed by Natera Inc.
- CO-FOUNDER Sheena Jonathan sold $478,945 worth of shares (1,500 units at $319.30) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form S-3ASR filed by Natera Inc.
- SEC Form S-8 filed by Natera Inc.
- CO-FOUNDER Sheena Jonathan sold $975,623 worth of shares (3,086 units at $316.14) as part of a pre-agreed trading plan and sold $19,781 worth of Common Stock (64 units at $309.08) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 214,462 units (SEC Form 4)
- Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer
- Amendment: SEC Form SCHEDULE 13G/A filed by Natera Inc.
- SEC Form 10-Q filed by Natera Inc.
- Natera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits